Meru Sandbox
Skip to content
Meru Sandbox
Search
Menu
Back to Risk of Reverse Seroconversion of Hepatitis B Virus Surface Antigen in Rituximab-Treated Non-Hodgkin Lymphoma Patients: A Large Cohort Retrospective Study.
Tzeon-Jye Chiou
Contributions
Showing
1 - 2
out of
2
Author
Published August 1, 2015
Author
Published September 1, 2015